Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2506 to 2520 of 9102 results

  1. Subcutaneous olanzapine for treating schizophrenia [TSID12289]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  4. Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over [TSID10761]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome [TSID9998]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. DV7103 for treating cystinuria in people 6 months and over [TSID10438]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Cytokine adsorption technologies for treating respiratory failure in people with COVID-19

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  8. MolecuLight i:X for wound imaging

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  9. Moor LDLS-BI for assessing burn depth and healing potential in children and adults

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  10. Ianalumab for treating active Sjogren's disease ID6634

    In development Reference number: GID-TA11836 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Surovatamig for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of treatment [ID6631]

    Awaiting development Reference number: GID-TA11849 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Leriglitazone for treating cerebral adrenoleukodystrophy in people 2 years and over [ID3903]

    In development Reference number: GID-HST10069 Expected publication date:  11 April 2027

    Highly specialised technologies guidance
    In development

  13. Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630]

    Awaiting development Reference number: GID-TA11837 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Deucravacitinib for treating active Sjogren's disease [ID6715]

    Awaiting development Reference number: GID-TA11939 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]

    Awaiting development Reference number: GID-TA11907 Expected publication date:  10 June 2027

    Technology appraisal guidance
    Awaiting development